The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

The YES intervention improved general and cancer-specific quality of life in AYA breast cancer survivors over six months.

The use of hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk according to results from ...

For 15 years, Suleika Jaouad has reported from the front lines of cancer treatment. Jaouad, the Emmy-winning journalist and ...

Rising healthcare costs and changing coverage increase financial burdens for individuals with hereditary conditions like ...

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma, by Bristol ...

Real and sham acupuncture were both linked to clinically meaningful and lasting improvements in perceived cognitive impairment compared with usual care for breast cancer survivors, but real ...

During the 2025 American Society of Hematology annual meeting, held earlier this month in Orlando, Florida, CURE sat down ...

High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast ...

Preoperative breast MRI did not improve LRR, DRFR, or OS outcomes in early-stage breast cancer patients. The trial involved ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...